SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Munch-a-Biotech Today
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: DewDiligence_on_SI9/27/2009 3:35:20 PM
   of 3158
 
ABT to Buy Solvay’s Drug Unit for $7B in Cash—WSJ:

siliconinvestor.com

This gives ABT full ownership over TriLipix, the successor to TriCor that has the potential to be a large-selling standalone drug (iHub #msg-34203456) and may have even bigger potential as one of the constituent drugs in Certriad (iHub #msg-38449725). In other words, ABT is getting a lot for the $7B deal price, IMO.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News